| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Oxypalmatine targets the PI3K/AKT signaling pathway, which plays a critical role in cell proliferation and survival. The compound also inhibits Wnt signaling by suppressing TCF/β-catenin-mediated transcriptional activity with an IC50 of 600.0 nM. It regulates apoptosis and may act on dopaminergic and other neurotransmitter systems. Its multiple targets make it a valuable compound for cancer and neurological research.
|
|---|---|
| ln Vitro |
Oxypalmatine demonstrates anti-cancer activity against breast cancer by inhibiting PI3K/AKT signaling. The compound inhibits Wnt signaling in human STF/293 cells by suppressing TCF/β-catenin-mediated transcriptional activity with an IC50 of 600.0 nM. It regulates breast cancer cell proliferation and apoptosis. These in vitro findings support its potential applications in cancer research, particularly breast cancer studies.
|
| ln Vivo |
In vivo studies of Oxypalmatine have demonstrated its efficacy in breast cancer-like organs. The compound has been studied for analgesic, anti-inflammatory, sedative, and neuroprotective effects. Research indicates it may act on dopaminergic and other neurotransmitter systems, contributing to its potential in managing pain, anxiety, and neurological disorders. However, comprehensive in vivo pharmacological studies are limited. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Oxypalmatine typically involve testing its effects on the PI3K/AKT signaling pathway. Cells are treated with varying concentrations of the compound and PI3K/AKT activity is assessed by measuring phosphorylation of downstream targets. Wnt signaling inhibition is evaluated using a superTOPflash reporter gene assay with an IC50 of 600.0 nM. The compound's purity and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Oxypalmatine involve culturing breast cancer cells to evaluate its anti-cancer activity. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. Apoptosis is quantified using flow cytometry with Annexin V/PI staining. Wnt signaling inhibition is assessed using reporter gene assays. Cell viability is assessed to ensure observed effects are not due to cytotoxicity. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Oxypalmatine would be conducted to evaluate its anti-cancer and neuroprotective activities. For breast cancer studies, tumor-bearing animals would be treated and tumor growth monitored. For neurological studies, animal models of pain, anxiety, and neurological disorders would be used. Parameters assessed would include tumor growth, behavioral outcomes, and tissue histopathology. Control groups receiving vehicle alone would be included for comparison.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Oxypalmatine reflect its nature as a berberine-type alkaloid. It has a molecular weight of 368.40 and the molecular formula C21H22NO5. As an alkaloid, it would be absorbed through the gastrointestinal tract and distributed throughout the body. The compound is expected to be metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Oxypalmatine has been evaluated in the context of its use as a research chemical. As a naturally occurring alkaloid from Phellodendron amurense, it is expected to have a safety profile similar to other berberine-type alkaloids. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
8-O-palmitine has reportedly been found in Coscinium fenestratum, Limaciopsis loangensis, and other organisms with available data.
Oxypalmatine (CAS# 19716-59-7) is also known as 8-Oxypalmatine. It has the molecular formula C21H22NO5 and a molecular weight of 368.40. The compound is a berberine-type alkaloid isolated from Phellodendron amurense. Oxypalmatine inhibits PI3K/AKT signaling and Wnt signaling (IC50 = 600.0 nM). It has been studied for anti-cancer, analgesic, anti-inflammatory, sedative, and neuroprotective effects. |
| Molecular Formula |
C21H21NO5
|
|---|---|
| Molecular Weight |
367.40
|
| Exact Mass |
367.142
|
| CAS # |
19716-59-7
|
| PubChem CID |
10926678
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.259
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C2=C(C=C1)C=C3C4=CC(=C(C=C4CCN3C2=O)OC)OC)OC
|
| InChi Key |
MZIUUCTTWZPXOV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21NO5/c1-24-16-6-5-13-9-15-14-11-18(26-3)17(25-2)10-12(14)7-8-22(15)21(23)19(13)20(16)27-4/h5-6,9-11H,7-8H2,1-4H3
|
| Chemical Name |
2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-8-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 33.33 mg/mL (90.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7218 mL | 13.6091 mL | 27.2183 mL | |
| 5 mM | 0.5444 mL | 2.7218 mL | 5.4437 mL | |
| 10 mM | 0.2722 mL | 1.3609 mL | 2.7218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
